>

Vertex Financial Statements Trends from 2010 to 2020

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>VRT</div>
VRTX -- USA Stock  

Fiscal Quarter End: March 31, 2020  

We have found one hundred twelve available fundamental trend indicators for Vertex Pharmaceuticals Incorpor which can be analyzed and compared to other ratios and to its competition. Make sure you double-check all of Vertex Pharmaceuticals Incorpor current market performance against the performance between 2010 and 2020 to make sure the company can sustain itself down the road. Vertex Pharmaceuticals Long Term Debt to Equity is fairly stable at the moment as compared to the last year. Vertex Pharmaceuticals reported Long Term Debt to Equity of 0.09 in 2019. Calculated Tax Rate is likely to grow to 16.87 in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop slightly above 905.3 M in 2020. Check Vertex Pharmaceuticals fundamental indicators over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 591 M, Cost of Revenue of 204.4 M or Gross Profit of 1.2 B, as well as many exotic indicators such as Interest Coverage of 18.07, Long Term Debt to Equity of 0.0908 or Calculated Tax Rate of 16.87. This can be a perfect complement to check Vertex Pharmaceuticals Valuation or Volatility. It can also complement various Vertex Pharmaceuticals Technical models. Also please take a look at the analysis of Vertex Pharmaceuticals Correlation with competitors.
Equity
Refresh
Revenues

Vertex Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.5 B8.3 B3.4 B
Increasing
Slightly volatile
Cash and EquivalentsB3.1 B1.4 B
Increasing
Slightly volatile
Investments356.8 M243.8 M485 M
Decreasing
Slightly volatile
Investments Current340 M225.6 M471.1 M
Decreasing
Slightly volatile
Investments Non Current30 M23.3 M26.4 M
Decreasing
Slightly volatile
Deferred Revenue14.9 M14.5 M51.9 M
Decreasing
Slightly volatile
Deposit Liabilities65.7 M66.1 M72 M
Decreasing
Slightly volatile
Property Plant and Equipment Net678.1 M628.5 M559.9 M
Increasing
Slightly volatile
Inventory78.1 M89.2 M68.9 M
Increasing
Very volatile
Trade and Non Trade Receivables195.3 M181 M151 M
Increasing
Slightly volatile
Trade and Non Trade Payables46.5 M55.3 M60.8 M
Decreasing
Very volatile
Goodwill and Intangible Assets437.6 M384.9 M381.4 M
Decreasing
Stable
Total Liabilities1.8 B2.2 B1.6 B
Increasing
Slightly volatile
Shareholders Equity6.6 B6.1 B2.4 B
Increasing
Slightly volatile
Accumulated Retained Earnings Deficit(6.3 B)(6.2 B)(4.5 B)
Decreasing
Slightly volatile
Accumulated Other Comprehensive Income20.6 M19.1 M10.5 M
Increasing
Slightly volatile
Current Assets1.4 B4.8 B2.1 B
Increasing
Slightly volatile
Assets Non CurrentB958.7 M908.2 M
Increasing
Slightly volatile
Current Liabilities506.3 M1.3 B648.5 M
Increasing
Slightly volatile
Liabilities Non Current596.3 M689.5 M746.8 M
Decreasing
Very volatile
Tax Liabilities10.8 M10.9 M11.8 M
Decreasing
Slightly volatile
Total Debt649.8 M756.7 M687.9 M
Increasing
Slightly volatile
Debt Current310.2 M287.5 M156.7 M
Increasing
Slightly volatile
Debt Non Current415.6 M469.2 M539.4 M
Decreasing
Very volatile
Shareholders Equity USD1.3 B1.2 B1.2 B
Increasing
Slightly volatile
Cash and Equivalents USD1.2 B1.1 B853.4 M
Increasing
Slightly volatile
Total Debt USD816.4 M756.7 M703.1 M
Increasing
Slightly volatile
Accounts Payable77.3 M87.6 M74.4 M
Increasing
Slightly volatile
Receivables683.5 M633.5 M265.6 M
Increasing
Slightly volatile
Inventories180.7 M167.5 M92.7 M
Increasing
Slightly volatile

Vertex Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues3.6 B4.2 B1.9 B
Increasing
Slightly volatile
Cost of Revenue204.4 M189.4 M155 M
Increasing
Slightly volatile
Selling General and Administrative Expense420.3 M389.5 M364.7 M
Increasing
Slightly volatile
Research and Development ExpenseB942.9 M859.3 M
Increasing
Slightly volatile
Operating Expenses1.4 B1.3 B1.3 B
Increasing
Slightly volatile
Interest Expense79.1 M73.3 M59 M
Increasing
Slightly volatile
Income Tax Expense16.2 M15 M3.1 M
Increasing
Stable
Net Loss Income from Discontinued Operations(67.6 M)(62.7 M)(68.8 M)
Increasing
Slightly volatile
Consolidated Income(104.3 M)(96.6 M)(231.6 M)
Increasing
Very volatile
Net Income to Non Controlling Interests27.2 M25.2 M(5.7 M)
Increasing
Stable
Net Income2.1 B1.2 B272.1 M
Increasing
Slightly volatile
Net Income Common Stock(139 M)(128.9 M)(226.2 M)
Increasing
Very volatile
Weighted Average Shares257.1 M256.7 M234.6 M
Increasing
Slightly volatile
Weighted Average Shares Diluted235.7 M260.7 M234.2 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(17.3 M)(16 M)(161.2 M)
Increasing
Stable
Revenues USD1.7 B1.5 B1.3 B
Increasing
Slightly volatile
Net Income Common Stock USD(139 M)(128.9 M)(226.2 M)
Increasing
Very volatile
Earning Before Interest and Taxes USD(17.3 M)(16 M)(161.2 M)
Increasing
Stable
Gross Profit1.2 B1.3 B1.1 B
Increasing
Slightly volatile
Operating Income1.3 B1.2 B55.9 M
Increasing
Slightly volatile
Direct Expenses591 M547.8 M239.8 M
Increasing
Slightly volatile

Vertex Pharmaceuticals Cash Flow Statement

Trends Matrix
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(70.2 M)(65 M)(55.3 M)
Decreasing
Slightly volatile
Net Cash Flow Business Acquisitions and Disposals(12.7 M)(11.8 M)(29.2 M)
Increasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals169.1 M156.7 M111.5 M
Increasing
Slightly volatile
Net Cash Flow from Financing159.2 M126.8 M159.7 M
Decreasing
Stable
Issuance Repayment of Debt Securities (9.2 M)(9 M)1.1 M
Increasing
Very volatile
Issuance Purchase of Equity Shares63 M61.4 M126.4 M
Decreasing
Stable
Net Cash Flow from Investing(1.3 B)(1.2 B)(268.7 M)
Decreasing
Slightly volatile
Net Cash Flow from Operations1.1 B1.6 B348.8 M
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (5.5 M)(5.4 M)(2.3 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents455.6 M422.3 M236.3 M
Increasing
Slightly volatile
Share Based Compensation230.8 M213.9 M177.1 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion44.3 M55.3 M49.9 M
Increasing
Slightly volatile

Fundamental Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share4.944.580.6184
Increasing
Slightly volatile
Earnings per Diluted Share8.244.510.8964
Increasing
Slightly volatile
Earnings per Basic Share USD(0.4467)(0.414)(0.9928)
Increasing
Stable
Return on Average Equity0.241422.3719(14.7381)
Increasing
Slightly volatile
Return on Average Assets17.4416.1601(3.2404)
Increasing
Slightly volatile
Return on Invested Capital(0.0087)(0.0081)(0.0836)
Increasing
Stable
Gross Margin97.4786.841790.7012
Decreasing
Stable
Profit Margin0.30528.2695(4.1757)
Increasing
Slightly volatile
EBITDA Margin38.7935.9526(2.5513)
Increasing
Slightly volatile
Return on Sales(0.0078)(0.0072)(0.2364)
Increasing
Slightly volatile
Asset Turnover0.51810.57160.5161
Increasing
Slightly volatile
Enterprise Value over EBITDA374347139
Increasing
Slightly volatile
Enterprise Value over EBIT(1.5 K)(1.5 K)(654)
Decreasing
Slightly volatile
Price to Earnings Ratio26.41(184)(58.3879)
Decreasing
Slightly volatile
Sales per Share17.516.21498.1412
Increasing
Slightly volatile
Price to Sales Ratio15.469.5316.3846
Decreasing
Very volatile
Price to Book Value10.6612.2913.6358
Increasing
Stable
Debt to Equity Ratio12.30.08851.6282
Increasing
Slightly volatile
Current Ratio3.443.61313.3038
Increasing
Stable
Free Cash Flow per Share15.545.81892.1132
Increasing
Slightly volatile
Book Value per Share4.254.915.1729
Decreasing
Slightly volatile
Tangible Assets Book Value per Share8.449.419.7059
Decreasing
Stable
Total Assets Per Share34.6532.118516.2132
Increasing
Slightly volatile
Cash Flow Per Share6.546.05941.5301
Increasing
Slightly volatile
Return on Investment22.1820.5584(8.9548)
Increasing
Slightly volatile
Operating Margin25.0128.7681(6.2317)
Increasing
Slightly volatile
Calculated Tax Rate16.8715.636(149)
Decreasing
Very volatile
Receivables Turnover9.847.94149.7742
Decreasing
Slightly volatile
Inventory Turnover3.293.75353.1646
Increasing
Very volatile
PPandE Turnover5.175.34694.1596
Decreasing
Stable
Cash and Equivalents Turnover1.851.44561.8672
Decreasing
Stable
Accounts Payable Turnover45.2341.922324.3982
Increasing
Slightly volatile
Accrued Expenses Turnover4.024.01084.4809
Increasing
Very volatile
Interest Coverage18.0716.755.6774
Increasing
Slightly volatile
Long Term Debt to Equity0.09080.08850.4538
Decreasing
Slightly volatile
Quick Ratio3.033.32763.0357
Increasing
Very volatile
Net Current Assets as percentage of Total Assets40.1541.930842.6922
Increasing
Very volatile
Revenue to Assets0.46290.50040.4729
Increasing
Stable

Vertex Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share4.944.580.6184
Increasing
Slightly volatile
Earnings per Diluted Share8.244.510.8964
Increasing
Slightly volatile
Earnings before Tax(118.4 M)(109.7 M)(224 M)
Increasing
Very volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA905.3 M1.5 B74.7 M
Increasing
Slightly volatile
Earnings per Basic Share USD(0.4467)(0.414)(0.9928)
Increasing
Stable
Earnings Before Interest Taxes and Depreciation Amortization USD58.9 M54.6 M(107 M)
Increasing
Stable
Market Capitalization56 B16.4 B20.2 B
Increasing
Slightly volatile
Enterprise Value53.1 B16.5 B19.9 B
Increasing
Slightly volatile
Invested Capital1.8 B1.7 B1.6 B
Increasing
Slightly volatile
Average Equity1.2 B1.1 B1.1 B
Increasing
Slightly volatile
Average Assets2.6 B2.4 B2.3 B
Increasing
Slightly volatile
Invested Capital Average1.2 B1.4 B1.5 B
Increasing
Stable
Tangible Asset Value2.5 B2.3 B2.2 B
Increasing
Slightly volatile
Return on Average Equity0.241422.3719(14.7381)
Increasing
Slightly volatile
Return on Average Assets17.4416.1601(3.2404)
Increasing
Slightly volatile
Free Cash Flow222.8 M206.5 M6.4 M
Increasing
Stable
Return on Invested Capital(0.0087)(0.0081)(0.0836)
Increasing
Stable
Gross Margin97.4786.841790.7012
Decreasing
Stable
Profit Margin0.30528.2695(4.1757)
Increasing
Slightly volatile
EBITDA Margin38.7935.9526(2.5513)
Increasing
Slightly volatile
Return on Sales(0.0078)(0.0072)(0.2364)
Increasing
Slightly volatile
Asset Turnover0.51810.57160.5161
Increasing
Slightly volatile
Enterprise Value over EBITDA374347139
Increasing
Slightly volatile
Enterprise Value over EBIT(1.5 K)(1.5 K)(654)
Decreasing
Slightly volatile
Price to Earnings Ratio26.41(184)(58.3879)
Decreasing
Slightly volatile
Sales per Share17.516.21498.1412
Increasing
Slightly volatile
Price to Sales Ratio15.469.5316.3846
Decreasing
Very volatile
Price to Book Value10.6612.2913.6358
Increasing
Stable
Debt to Equity Ratio12.30.08851.6282
Increasing
Slightly volatile
Current Ratio3.443.61313.3038
Increasing
Stable
Working Capital900.8 M935.1 MB
Increasing
Very volatile
Free Cash Flow per Share15.545.81892.1132
Increasing
Slightly volatile
Book Value per Share4.254.915.1729
Decreasing
Slightly volatile
Tangible Assets Book Value per Share8.449.419.7059
Decreasing
Stable
Total Assets Per Share34.6532.118516.2132
Increasing
Slightly volatile
Cash Flow Per Share6.546.05941.5301
Increasing
Slightly volatile
Revenue Per Employee1.5 M1.4 M816.1 K
Increasing
Slightly volatile
Net Income Per Employee423.2 K392.3 K27.3 K
Increasing
Slightly volatile
Return on Investment22.1820.5584(8.9548)
Increasing
Slightly volatile
Operating Margin25.0128.7681(6.2317)
Increasing
Slightly volatile
Calculated Tax Rate16.8715.636(149)
Decreasing
Very volatile
Receivables Turnover9.847.94149.7742
Decreasing
Slightly volatile
Inventory Turnover3.293.75353.1646
Increasing
Very volatile
PPandE Turnover5.175.34694.1596
Decreasing
Stable
Cash and Equivalents Turnover1.851.44561.8672
Decreasing
Stable
Accounts Payable Turnover45.2341.922324.3982
Increasing
Slightly volatile
Accrued Expenses Turnover4.024.01084.4809
Increasing
Very volatile
Interest Coverage18.0716.755.6774
Increasing
Slightly volatile
Long Term Debt to Equity0.09080.08850.4538
Decreasing
Slightly volatile
Quick Ratio3.033.32763.0357
Increasing
Very volatile
Net Current Assets as percentage of Total Assets40.1541.930842.6922
Increasing
Very volatile
Revenue to Assets0.46290.50040.4729
Increasing
Stable

Vertex Fundamental Market Drivers

Short Percent Of Float1.36%
Forward Price Earnings22.66
Shares Short Prior Month3.59M
Average Daily Volume Last 10 Day1.36M
Average Daily Volume In Three Month1.34M
Date Short InterestJanuary 31, 2020
Fifty Day Average235.63
Two Hundred Day Average204.43

Vertex Upcoming Events

Upcoming Quarterly Earning ReportMay 5, 2020
Next Earnings ReportJuly 29, 2020
Next Fiscal Quarter EndMarch 31, 2020
Next Fiscal Year EndFebruary 4, 2021
Last Quarter Report DateDecember 31, 2019
Last Earning Anouncement DateMarch 31, 2019

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  

Vertex Pharmaceuticals Fundamental Drivers

Vertex Pharmaceuticals Incorpor Fundamental Market Drivers

Short Percent Of Float1.36%
Forward Price Earnings22.66
Shares Short Prior Month3.59M
Average Daily Volume Last 10 Day1.36M
Average Daily Volume In Three Month1.34M
Date Short InterestJanuary 31, 2020
Fifty Day Average235.63
Two Hundred Day Average204.43

Vertex Pharmaceuticals Upcoming Events

Vertex Pharmaceuticals Upcoming Company Events

Upcoming Quarterly Earning ReportMay 5, 2020
Next Earnings ReportJuly 29, 2020
Next Fiscal Quarter EndMarch 31, 2020
Next Fiscal Year EndFebruary 4, 2021
Last Quarter Report DateDecember 31, 2019
Last Earning Anouncement DateMarch 31, 2019
Also please take a look at the analysis of Vertex Pharmaceuticals Correlation with competitors. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..